References
- Berg K. J., Jakobsen J. A. Nephrotoxicity related to contrast media. Patient safety and adverse events in contrast medium experiments, I. Enge, J. Edgren. Elsevier Science Publishers (Biomedical Division), Amsterdam 1989; 111
- Berns A. S. Nephrotoxicity of contrast media. Kidney Int 1989; 36: 730
- Goldstein H. A., Kashanion F. K., Blumetti R. F. Safety assessment of gadopentetate dimeglumine in US clinical trials. Radiology 1990; 174: 17
- Greco A., McNamara M. T., Lanthiez P. Gadodiamide injection. Non-ionic gadolinium chelate for MR imaging of the brain and spine. Radiology 1990; 176: 451
- Haustein J., Laniado M., Niendorf H.-P. Triple-dose versus standard dose gadopentetate dimeglumine. A randomized study in 199 patients. Radiology 1993; 186: 855
- Lundby B., Berg K. J., Lien H. H. A double blind study to evaluate the tolerability of gadodiamide injection and its effect on renal function in patients undergoing cerebral magnetic resonance imaging. Br. J. Radiol 1993; 66: 871
- Niendorf H.-P., Dinger J. C., Haustein J. Tolerance data of Gd-DTPA. A review. Eur. J. Radiol 1991; 13: 15
- Runge V. M., Kirsch J. E., Thomas G. S. High dose applications of gadolinium chelates in magnetic resonance imaging. Magn. Reson. Med 1991; 22: 358
- Svaland M. G., Skalpe I., Bakke S. J. A double-blind study to evaluate the efficacy and tolerability of a higher dose of gadodiamide injection as a contrast medium in MR imaging. 1994, In manuscript
- Sze G., Brant-Zawadzki M., Haughton V. Multicenter study of gadodiamide injection as a contrast agent in MR imaging of the brain and spine. Radiology 1991; 181: 693
- Van Wagoner M., O'Toole M., Quay S. Non-ionic magnetic resonance imaging contrast agents. Clinical trial experience of safety, tolerance and efficacy of gadodiamide injection. Invest. Radiol 1990; 25: 39
- Yuh W. T. C., Fisher D. J., Engelken J. D. MR evaluation of CNS tumors. Dose comparison study with gadopentetate dimeglumine and gadoteridol. Radiology 1991; 180: 485